Gilead Sciences (GILD) Cost of Revenue (2009 - 2026)

Gilead Sciences has reported Cost of Revenue for 18 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 6.17% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $6.1 billion (down 1.6% YoY), and the FY2025 full-year result was $6.2 billion, changed 0.27% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.4 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Cost of Revenue was $2.1 billion in Q4 2023, with the low at $1.4 billion in Q3 2022.
• Historically, Cost of Revenue has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2025.
• Annual changes were most pronounced in 2022 — Cost of Revenue plunged 46.86% — and 2023, when it jumped 49.71%.
• Gilead Sciences' Cost of Revenue stood at $1.4 billion in 2022, then jumped by 49.71% to $2.1 billion in 2023, then retreated by 24.35% to $1.6 billion in 2024, then climbed by 2.72% to $1.6 billion in 2025, then declined by 11.02% to $1.4 billion in 2026.
• The last three Cost of Revenue figures came in at $1.4 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.